ArticleChemical & biomedical imaging2026
Fluorescence Discrimination of Cancer from Inflammation by Selective Targeting Folate Receptor α.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy and surgical outcomes of fluorescence-guided surgery in breast cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2026Pooled it
- ROS-Activatable "off-on" Fluorescent Prodrug Loaded Micelles for Targeted Therapy and in Situ Imaging of Breast Cancer Cells.International journal of pharmaceutics: X · 2026Article
- A renally clearable tumor-targeted probe enabling functional delineation of tumor margins by NIR-II fluorescence lifetime imaging.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present NY-07, an antifolate dye conjugate capable of intrasurgical discrimination between inflammatory and cancerous tissues. This capability addresses a longstanding problem in fluorescence-guided surgery, where the current FDA-approved probes exhibit false-positive rates of 25-68% due to nonspecific accumulation in inflammatory tissue, leading to unnecessary tissue resection and increased surgical morbidity. NY-07 selectively targets folate receptor α (FRα) overexpressed in tumors while exhibiting 8-fold reduced affinity for folate receptor β (FRβ) predominantly found on inflammatory macrophages (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.